Veterinary tetanus toxoid API is a detoxified Clostridium tetani toxin antigen supplied as a sterile liquid concentrate or lyophilized powder for parenteral vaccine manufacture. Tablet, capsule, granule, and feed premix presentations are excluded from downstream application because oral administration does not induce the required systemic antitetanus immunity and the antigen is degraded in the gastrointestinal tract. The scenarios that follow are confined to authorized vaccine manufacturing routes: liquid aluminum-adjuvanted injections, combination clostridial vaccines, lyophilized intermediates, autogenous biologicals, and equine combination viral-toxoid injections.

Equine Immunization Programs Depend on a Narrow Flocculation Acceptance Window

The equine injectable route is the dominant downstream use of tetanus toxoid veterinary API because horses are highly susceptible to Clostridium tetani wound infection. Formulation of a monovalent aluminum-adsorbed injection is carried out in a jacketed stainless-steel vessel equipped with a bottom-mounted low-shear impeller operating at 100–300 rpm; adsorption onto 2% w/v aluminum hydroxide gel is allowed to proceed for 18–24 h at 20–25 °C and pH 6.0–7.0. The antigen concentrate is metered into the adjuvant-preservative matrix at 8–15% v/v when the concentrate is standardized to 50–100 Lf/mL, yielding a final dose of 5–10 Lf in 2 mL. Aluminum content is controlled at 1.0–1.5 mg Al per dose. The detoxified toxoid concentrate is sterile-filtered through 0.22 µm polyethersulfone membranes before adsorption, and the final adjuvanted suspension is aseptically filled because post-adsorption filtration would remove the antigen-adjuvant complex. Compliance for the equine monovalent presentation is anchored to 9 CFR 113.117 for tetanus toxoid potency and safety, with final lot sterility verified by Ph. Eur. 2.6.1. Terminal product types include 1 mL and 2 mL Type I glass vials and prefilled syringes for intramuscular administration.

In ovine and caprine flock health programs, tetanus toxoid is included in multivalent clostridial suspensions used to protect ewes, does, and lambs against tetanus and enterotoxemia. The tetanus component is standardized separately against reference Clostridium tetani antitoxin and then blended with Clostridium perfringens type C and type D toxoids that have been independently inactivated with formaldehyde not exceeding 0.4% w/v at 37 °C for 21–30 days. The addition proportion of tetanus toxoid concentrate in the final blend is 5–10% v/v, corresponding to 5 Lf per 2 mL dose when bulk potency is 100 Lf/mL. Aluminum hydroxide gel is added to a final concentration of 1.5–2.0 mg Al per dose, and the suspension is homogenized under low-shear conditions to avoid disruption of the adjuvant gel structure. Compliance is tied to 9 CFR 113.117 for the tetanus component and Ph. Eur. 2.6.1 sterility; batch release includes guinea pig challenge for residual toxicity and residual formaldehyde assay. Finished products are multidose Type I glass or polyethylene terephthalate vials of 100 mL, 250 mL, and 500 mL, intended for subcutaneous injection through automatic syringe equipment.

Bovine Clostridial Blends and the 8-Way Suspension Platform

Bovine clostridial vaccines that include tetanus toxoid are produced for feedlot, cow-calf, and dairy operations where castration, dehorning, calving trauma, or banding creates anaerobic wound environments. Manufacturers ferment Clostridium tetani in stirred-tank anaerobic bioreactors on casein hydrolysate medium, remove cells by tangential-flow filtration, detoxify the clarified toxin with formaldehyde at 0.3–0.5% w/v and 37 °C, and concentrate the toxoid by ultrafiltration using a molecular weight cut-off selected to retain toxoid while removing media-derived peptides. The tetanus toxoid fraction is added at 4–8% v/v of the final pool to supply 2.5–5 Lf per 2 mL dose in an 8-way combination; each other clostridial fraction is standardized independently before pooling to prevent immune interference. Sterile 0.22 µm filtration is performed before aluminum salt adsorption, and the final bulk is aseptically filled into 10 mL, 50 mL, and 250 mL Type II glass or high-density polyethylene vials. Compliance for the tetanus component follows 9 CFR 113.117, with final lot sterility per Ph. Eur. 2.6.1; potency is established by parallel-line guinea pig challenge. Terminal product types include blackleg/tetanus combinations and broader 7-way/8-way clostridial injections for subcutaneous use in cattle.

When Lyophilized Antigen Concentrate is Rehydrated Below 2.0% Residual Moisture

The lyophilized presentation of tetanus toxoid API is used when a downstream manufacturer requires a thermostable antigen intermediate or intends to blend the toxoid with adjuvants at a later fill-finish site. Liquid bulk toxoid is formulated with a cryoprotectant matrix before lyophilization; published data for veterinary tetanus toxoid lyophilized specifically in this configuration is limited, but development records indicate that 5–10% w/v trehalose or mannitol and 0.5–1.0% w/v glycine are used to protect flocculation activity during freezing and dehydration. The addition proportion of cryoprotectant to antigen solution is not a fixed formulation rule and must be confirmed by freeze-drying microscopy and differential scanning calorimetry for the collapse temperature of the chosen matrix. The process uses a shelf lyophilizer with product temperature ramped to -40 °C, primary drying at -20 °C and chamber pressure of 80–150 µbar, and secondary drying at 25 °C until residual moisture is below 2.0%. Sterility is maintained by filtration through 0.22 µm membranes before lyophilization, and the final cake is sealed under nitrogen in Type I glass vials. Compliance for the sterile intermediate follows Ph. Eur. 2.6.1, and stability is evaluated under ICH Q1A accelerated storage conditions. Terminal product types include single-dose lyophilized vaccine for reconstitution with isotonic diluent and bulk lyophilized antigen for integration into multicomponent diluent-filled syringe programs.

Autogenous veterinary biological manufacturing uses tetanus toxoid API to formulate prescription products for a single herd, flock, or production site under national autogenous licensing pathways. The downstream processor receives a standardized liquid toxoid concentrate, verifies identity by flocculation against Clostridium tetani antitoxin, and prepares a fixed-composition suspension for a defined epidemiological unit. The addition proportion is determined by the veterinarian’s requested potency and the bulk Lf value; in practice, the toxoid concentrate commonly occupies 10–30% v/v of the finished suspension, with final dose calibrated to 5 Lf per 2 mL, but published data for specific autogenous configurations is limited and each batch is adjusted against the reference toxoid. The process includes fermentation of the herd isolate, formaldehyde inactivation at 0.3–0.4% w/v until no residual toxin is detectable by guinea pig inoculation, purification by ammonium sulfate fractionation and ultrafiltration, sterile filtration through 0.22 µm membranes, and aseptic filling into crimped-use vials. Aluminum hydroxide is used at 1.0–2.0 mg Al per dose where an adjuvant is prescribed; oil-emulsion formulations are introduced only after local safety testing. Compliance is governed by 9 CFR 113.113 in the United States and by national autogenous vaccine orders in the EU, with batch sterility tested by Ph. Eur. 2.6.1. Terminal dosage forms are injectable suspensions or emulsions in 20 mL, 50 mL, and 100 mL prescription vials.

For Equine Combination Vaccines That Present Tetanus Toxoid With Inactivated Viral Fractions

In equine combination vaccines, tetanus toxoid is combined with inactivated equine influenza, equine herpesvirus, and equine encephalomyelitis virus antigen fractions in a single parenteral dose. The tetanus toxoid is adsorbed onto aluminum hydroxide separately before the viral antigens are added, preventing premature aggregation between the anionic toxoid and residual viral matrix proteins. The toxoid concentrate is included at 5–8% v/v of the final blend, calibrated to 5 Lf per 1 mL dose, while the final aluminum content is maintained at 1.0–1.5 mg Al per dose. The viral fractions are inactivated with binary ethylenimine or formalin and quantified by antigen mass or potency assay before pooling. Final bulk is homogenized in a stainless-steel closed system under low-shear agitation for 60–120 min at 4–8 °C, then aseptically filled into 1 mL or 2 mL Type I glass prefilled syringes or vials. Compliance for the tetanus component uses 9 CFR 113.117; finished product sterility is verified by Ph. Eur. 2.6.1, and freedom from residual live virus is demonstrated by appropriate cell culture methods. Terminal product types include monovalent dose syringes and multi-antigen companion-animal vaccination presentations.